Progressive Improvements Made in Stem Cell Therapy Open the Floodgates of Opportunities for Mesenchymal Stem Cells (MSCs) as the Most Potent of all Types of Stem Cells
The
global market for Mesenchymal Stem Cells (MSCs) is projected to exceed US$7.1
billion by 2022, driven by encouraging progress being achieved in the field
of stem cell therapy and the ensuing focus on the numerous therapeutic
possibilities of MSCs in cellular therapies and tissue engineering.
Mesenchymal Stem Cells (MSCs) are gradually gaining
therapeutic interest as they are increasingly considered to have the potential
to treat various degenerative and acute diseases. MSCs are mainly used for
replacing or repairing damaged tissues. Application of MSCs in various
therapeutic areas is largely due to the cells’ ability to differentiate into a
broad array of cells, and also due to their localization properties. The cells
have the ability to easily migrate to tissue injury or tumor sites which helps
in targeted delivery of therapeutic medication. Therapeutic agents can be
introduced precisely at the target sites with the help of MSC
gene therapies. MSCs have the
potential to be used for releasing bioactive molecules to stimulate recovery of
injured cells. MSCs are additionally known for their robust immunosuppressive
properties because of which, they are expected to be further exploited by
researchers for developing heterologous as well as autologous therapies for
various diseases in the near future. The
growth in the market is benefiting from the rapidly aging population, rising
incidence of chronic
diseases, government support in
the form of favorable regulations and funding, and rising investments in the
area of stem cell-biology. MSCs are also being increasingly used for
substituting operative procedures such as knee-replacement surgeries. Collaborations and partnerships, and
increased emphasis on innovation constitute the key trends in the market. There
is also a growing interest in conducting further research on MSCs for exploring
their potential in tissue engineering as well as cellular therapy.
As stated by the new market research report on Mesenchymal
Stem Cells, the United States represents
the largest market worldwide. Asia-Pacific ranks as the fastest growing market led
by India and China. Large pool of patients who can be treated with MSC
therapies; increasing governmental support and funding for popularizing MSC
therapies as part of larger healthcare improvement strategies; developing healthcare
infrastructure; growing GDP, rising living standards and higher healthcare
spending represent major factors driving growth in China and India.
Key players in the market include Cell Applications Inc.,
Celprogen Inc., Cyagen US Inc., Genlantis Inc., Lonza Group, Mesoblast Limited,
MilliporeSigma, Neuromics, Orthofix International N.V., PromoCell GmbH, R&D
Systems Inc., ScienCell Research Laboratories, Stemcell Technologies Inc.,
Stemedica Cell Technologies Inc., Thermo Fischer Scientific Inc., Vitro
Biopharma, among others.
The research report titled "Mesenchymal
Stem Cells – Market Analysis, Trends, and Forecasts"
announced by Global Industry Analysts Inc.,
provides a comprehensive review of the market, industry overview, trends,
growth drivers, latest product launches and recent industry activity. The
report provides market estimates and projections in US dollars for major
geographic markets including the United States, Canada, Japan, Europe, Asia-Pacific,
and Rest of World.
Global Industry Analysts, Inc.
6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.
For
enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.
For cutting edge analyst reviews on top industries,
follow us on Twitter and connect with us on LinkedIn
Comments
Post a Comment